For appointments

Call the office

Folsom, California Office: 916-983-4444

Call Now

Close

WHO:

Dr. Gish is a Hepatologist specializing in all forms of liver disease, liver cancer and liver transplant. Dr. Gish has partnered with TeleMed2U to provide telemedicine consultative services for patients with liver disease.

WHAT:

TeleMed2U is a telemedicine-based multi-specialty clinical practice increasing access to specialist providers providing, “healthcare anywhere and everywhere.” The telemedicine consultation will be conducted through our HIPAA and HITECH compliant platform. Connectivity testing will be done in advance to ensure you can connect via our telemedicine platform. Following the consultation, a clinical note will be provided including a summary of your liver consultation with Dr. Gish and his consultative recommendations.

COST:

Payment will be processed through an online secure transaction portal. The fees for consultative services are:

Initial 60 minute consultation per patient: $500.00
Follow Up 30 minute consultation per patient: $300.00

NEXT STEPS:

If you’d like to continue, please click Next to complete the form and we will contact you to schedule connectivity testing. During the test you will have the opportunity to determine the method of providing medical records, discuss appointment availability as well as discuss any additional questions that you have. If you are a healthcare facility interested in services, please complete the form and we can discuss the options that are right for you and your patients.

Email

Subject

Country

You should be aware of the general risks of transmitting information over the Internet, which may not use encryption. You should therefore not share any personal medical information that you would wish to be held confidential in a physician/patient or similar clinical relationship.

The information contained on this website is not intended, should not substitute for, or be used instead of, a clinical or therapeutic relationship with a health care professional who is fully familiar with the specifics of your case. The information on this site may assist you in your personal, general research but none of it constitutes the practice of medicine or any other health care profession.

Nothing in this site is intended as a recommendation or endorsement of any specific tests, products, procedures, healthcare provider, opinions, or other information that may be mentioned in this site. Any reliance on any information provided by the website personnel, others appearing on the site at the invitation of the website and/or other visitors to the site is solely at the user's risk.

E-mail correspondence with Dr. Robert G. Gish Consultants, LLC or any of its employees, or agents, does not create a physician/patient relationship between us or cause Dr. Gish to create or retain any medical records about you, monitor your care, or communicate with your own health care provider.

Always seek the advice of your physician or other qualified health care provider with any questions you have regarding your medical care. If you suspect that you may have a medical condition, or are seeking medical advice or treatment, we recommend that you consult a qualified health professional as soon as possible.

Powered by

Close Form

Emmet B. Keeffe Symposium - Insulin Resistance and NAFLD

Feb 27, 2018

The Division of Gastroenterology & Hepatology, Department of Medicine - Stanford University School of Medicine

Presents: Emmet B. Keeffe Liver Symposium

“Insulin Resistance and Non-Alcoholic Fatty Liver Disease”

Friday, March 9, 2018, 10:00 am - 4:30 pm

Li Ka Shing Center (LKSC), Berg Hall, 2nd Floor

291 Campus Drive, Stanford University

Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in the US. Its prevalence is rising, rapidly becoming a leading cause for liver transplantation. NAFLD is a part of the systemic manifestations of insulin resistance often seen in patients with prediabetes and diabetes.

This year’s Emmet Keeffe Liver Symposium focuses on NAFLD and insulin resistance. We will first discuss the latest research on insulin resistance, prediabetes and type II diabetes which is fundamental to the understanding of NAFLD. The latter part of the symposium will address the clinical aspects of NAFLD in a multidisciplinary fashion.

Our Keynote Speaker this year is Dr. Ira Jacobson, a renowned hepatologist and clinical researcher, who is currently the Director of Hepatology at NYU Langone Medical Center. He will present “NAFLD: state of the art in practice 2018.”

View/Register

Metadata